Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma
- Autores
- Tellado, Matías Nicolás; De Robertis, Mariangela; Montagna, Daniela Romina; Giovannini, Daniela; Salgado, Sergio; Michinski, Sebastián Diego; Signori, Emanuela; Maglietti, Felipe Horacio
- Año de publicación
- 2023
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Electrochemotherapy (ECT) is a standard of care in veterinary and human oncology. The treatment induces a well-characterized local immune response which is not able to induce a systemic response. In this retrospective cohort study, we evaluated the addition of gene electrotransfer (GET) of canine IL-2 peritumorally and IL-12 intramuscularly to enhance the immune response. Thirty canine patients with inoperable oral malignant melanoma were included. Ten patients received ECT+GET as the treatment group, while twenty patients received ECT as the control group. Intravenous bleomycin for the ECT was used in both groups. All patients had compromised lymph nodes which were surgically removed. Plasma levels of interleukins, local response rate, overall survival, and progression-free survival were evaluated. The results show that IL-2 and IL-12 expression peaked around days 7–14 after transfection. Both groups showed similar local response rates and overall survival times. However, progression-free survival resulted significantly better in the ECT+GET group, which is a better indicator than overall survival, as it is not influenced by the criterion used for performing euthanasia. We can conclude that the combination of ECT+GET using IL-2 and IL-12 improves treatment outcomes by slowing down tumoral progression in stage III–IV inoperable canine oral malignant melanoma.
Fil: Tellado, Matías Nicolás. No especifíca;
Fil: De Robertis, Mariangela. Università degli Studi di Bari; Italia
Fil: Montagna, Daniela Romina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Giovannini, Daniela. No especifíca;
Fil: Salgado, Sergio. No especifíca;
Fil: Michinski, Sebastián Diego. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Signori, Emanuela. No especifíca;
Fil: Maglietti, Felipe Horacio. Instituto Universidad de la Fundación "Héctor Barceló"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina - Materia
-
CANCER
DOG
ECT
EGT
ELECTROGENE TRANSFER
ELECTROPORATION
IMMUNE RESPONSE
IMMUNOTHERAPY - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/221280
Ver los metadatos del registro completo
id |
CONICETDig_8fe0c3869022dc62fc6c82c15adc8745 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/221280 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant MelanomaTellado, Matías NicolásDe Robertis, MariangelaMontagna, Daniela RominaGiovannini, DanielaSalgado, SergioMichinski, Sebastián DiegoSignori, EmanuelaMaglietti, Felipe HoracioCANCERDOGECTEGTELECTROGENE TRANSFERELECTROPORATIONIMMUNE RESPONSEIMMUNOTHERAPYhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Electrochemotherapy (ECT) is a standard of care in veterinary and human oncology. The treatment induces a well-characterized local immune response which is not able to induce a systemic response. In this retrospective cohort study, we evaluated the addition of gene electrotransfer (GET) of canine IL-2 peritumorally and IL-12 intramuscularly to enhance the immune response. Thirty canine patients with inoperable oral malignant melanoma were included. Ten patients received ECT+GET as the treatment group, while twenty patients received ECT as the control group. Intravenous bleomycin for the ECT was used in both groups. All patients had compromised lymph nodes which were surgically removed. Plasma levels of interleukins, local response rate, overall survival, and progression-free survival were evaluated. The results show that IL-2 and IL-12 expression peaked around days 7–14 after transfection. Both groups showed similar local response rates and overall survival times. However, progression-free survival resulted significantly better in the ECT+GET group, which is a better indicator than overall survival, as it is not influenced by the criterion used for performing euthanasia. We can conclude that the combination of ECT+GET using IL-2 and IL-12 improves treatment outcomes by slowing down tumoral progression in stage III–IV inoperable canine oral malignant melanoma.Fil: Tellado, Matías Nicolás. No especifíca;Fil: De Robertis, Mariangela. Università degli Studi di Bari; ItaliaFil: Montagna, Daniela Romina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Giovannini, Daniela. No especifíca;Fil: Salgado, Sergio. No especifíca;Fil: Michinski, Sebastián Diego. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Signori, Emanuela. No especifíca;Fil: Maglietti, Felipe Horacio. Instituto Universidad de la Fundación "Héctor Barceló"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaMDPI2023-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/221280Tellado, Matías Nicolás; De Robertis, Mariangela; Montagna, Daniela Romina; Giovannini, Daniela; Salgado, Sergio; et al.; Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma; MDPI; Vaccines; 11; 6; 5-2023; 1-162076-393XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2076-393X/11/6/1033info:eu-repo/semantics/altIdentifier/doi/10.3390/vaccines11061033info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:04:38Zoai:ri.conicet.gov.ar:11336/221280instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:04:38.916CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma |
title |
Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma |
spellingShingle |
Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma Tellado, Matías Nicolás CANCER DOG ECT EGT ELECTROGENE TRANSFER ELECTROPORATION IMMUNE RESPONSE IMMUNOTHERAPY |
title_short |
Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma |
title_full |
Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma |
title_fullStr |
Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma |
title_full_unstemmed |
Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma |
title_sort |
Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma |
dc.creator.none.fl_str_mv |
Tellado, Matías Nicolás De Robertis, Mariangela Montagna, Daniela Romina Giovannini, Daniela Salgado, Sergio Michinski, Sebastián Diego Signori, Emanuela Maglietti, Felipe Horacio |
author |
Tellado, Matías Nicolás |
author_facet |
Tellado, Matías Nicolás De Robertis, Mariangela Montagna, Daniela Romina Giovannini, Daniela Salgado, Sergio Michinski, Sebastián Diego Signori, Emanuela Maglietti, Felipe Horacio |
author_role |
author |
author2 |
De Robertis, Mariangela Montagna, Daniela Romina Giovannini, Daniela Salgado, Sergio Michinski, Sebastián Diego Signori, Emanuela Maglietti, Felipe Horacio |
author2_role |
author author author author author author author |
dc.subject.none.fl_str_mv |
CANCER DOG ECT EGT ELECTROGENE TRANSFER ELECTROPORATION IMMUNE RESPONSE IMMUNOTHERAPY |
topic |
CANCER DOG ECT EGT ELECTROGENE TRANSFER ELECTROPORATION IMMUNE RESPONSE IMMUNOTHERAPY |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Electrochemotherapy (ECT) is a standard of care in veterinary and human oncology. The treatment induces a well-characterized local immune response which is not able to induce a systemic response. In this retrospective cohort study, we evaluated the addition of gene electrotransfer (GET) of canine IL-2 peritumorally and IL-12 intramuscularly to enhance the immune response. Thirty canine patients with inoperable oral malignant melanoma were included. Ten patients received ECT+GET as the treatment group, while twenty patients received ECT as the control group. Intravenous bleomycin for the ECT was used in both groups. All patients had compromised lymph nodes which were surgically removed. Plasma levels of interleukins, local response rate, overall survival, and progression-free survival were evaluated. The results show that IL-2 and IL-12 expression peaked around days 7–14 after transfection. Both groups showed similar local response rates and overall survival times. However, progression-free survival resulted significantly better in the ECT+GET group, which is a better indicator than overall survival, as it is not influenced by the criterion used for performing euthanasia. We can conclude that the combination of ECT+GET using IL-2 and IL-12 improves treatment outcomes by slowing down tumoral progression in stage III–IV inoperable canine oral malignant melanoma. Fil: Tellado, Matías Nicolás. No especifíca; Fil: De Robertis, Mariangela. Università degli Studi di Bari; Italia Fil: Montagna, Daniela Romina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina Fil: Giovannini, Daniela. No especifíca; Fil: Salgado, Sergio. No especifíca; Fil: Michinski, Sebastián Diego. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Signori, Emanuela. No especifíca; Fil: Maglietti, Felipe Horacio. Instituto Universidad de la Fundación "Héctor Barceló"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina |
description |
Electrochemotherapy (ECT) is a standard of care in veterinary and human oncology. The treatment induces a well-characterized local immune response which is not able to induce a systemic response. In this retrospective cohort study, we evaluated the addition of gene electrotransfer (GET) of canine IL-2 peritumorally and IL-12 intramuscularly to enhance the immune response. Thirty canine patients with inoperable oral malignant melanoma were included. Ten patients received ECT+GET as the treatment group, while twenty patients received ECT as the control group. Intravenous bleomycin for the ECT was used in both groups. All patients had compromised lymph nodes which were surgically removed. Plasma levels of interleukins, local response rate, overall survival, and progression-free survival were evaluated. The results show that IL-2 and IL-12 expression peaked around days 7–14 after transfection. Both groups showed similar local response rates and overall survival times. However, progression-free survival resulted significantly better in the ECT+GET group, which is a better indicator than overall survival, as it is not influenced by the criterion used for performing euthanasia. We can conclude that the combination of ECT+GET using IL-2 and IL-12 improves treatment outcomes by slowing down tumoral progression in stage III–IV inoperable canine oral malignant melanoma. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-05 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/221280 Tellado, Matías Nicolás; De Robertis, Mariangela; Montagna, Daniela Romina; Giovannini, Daniela; Salgado, Sergio; et al.; Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma; MDPI; Vaccines; 11; 6; 5-2023; 1-16 2076-393X CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/221280 |
identifier_str_mv |
Tellado, Matías Nicolás; De Robertis, Mariangela; Montagna, Daniela Romina; Giovannini, Daniela; Salgado, Sergio; et al.; Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma; MDPI; Vaccines; 11; 6; 5-2023; 1-16 2076-393X CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2076-393X/11/6/1033 info:eu-repo/semantics/altIdentifier/doi/10.3390/vaccines11061033 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
MDPI |
publisher.none.fl_str_mv |
MDPI |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269867686756352 |
score |
13.13397 |